abrdn plc Makes New $4.70 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

abrdn plc purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 154,269 shares of the company’s stock, valued at approximately $4,704,000.

Several other large investors also recently made changes to their positions in NTLA. ARK Investment Management LLC increased its position in shares of Intellia Therapeutics by 14.7% in the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after acquiring an additional 1,463,820 shares in the last quarter. Rhenman & Partners Asset Management AB increased its position in shares of Intellia Therapeutics by 1,600.0% in the third quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock worth $26,877,000 after acquiring an additional 800,000 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Intellia Therapeutics by 13.8% in the fourth quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock worth $61,477,000 after acquiring an additional 244,722 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Intellia Therapeutics by 3.7% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock worth $111,312,000 after acquiring an additional 125,639 shares in the last quarter. Finally, Capital Advisors Inc. OK increased its position in shares of Intellia Therapeutics by 34.7% in the fourth quarter. Capital Advisors Inc. OK now owns 284,738 shares of the company’s stock worth $8,682,000 after acquiring an additional 73,379 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Trading Up 3.7 %

NASDAQ NTLA opened at $20.76 on Friday. Intellia Therapeutics, Inc. has a 12 month low of $19.37 and a 12 month high of $47.48. The company’s fifty day moving average price is $26.51 and its two-hundred day moving average price is $27.54.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The firm had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. During the same period in the prior year, the firm posted ($1.40) EPS. Analysts predict that Intellia Therapeutics, Inc. will post -5.57 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the transaction, the executive vice president now directly owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $136.00 to $32.00 in a report on Friday, February 23rd. Wolfe Research began coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.